From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Topics>
  3. STDs>
  4. Archives

STDs: Archives

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.

Items 426-450 of 509 are shown

The Survival Benefit of HIV Treatment in the U.S.

Treatment of HIV infection and prevention of mother-to-child HIV transmission have saved 3 million life-years in the U.S. alone.

Gardasil: A Quadrivalent Human Papillomavirus Vaccine

Newly licensed by the FDA, this vaccine was developed to protect against HPV-induced genital warts, precancerous genital lesions, and cervical cancer.

Length of HPV Vaccine Protection

An HPV vaccine offered protection against HPV 16 and 18 throughout this extended follow-up study.

Obstetric Risks of Protease Inhibitors During Pregnancy

Combination therapy including a protease inhibitor during pregnancy increased the risk for preterm delivery.

Management of Abnormal Cervical Cytology: Age Matters

Abnormal findings in adolescents may be monitored with repeat cytology at 6 and 12 months.

Bacterial Vaginosis: Do High Recurrence Rates Suggest Sexual Transmission?

Over half of women with bacterial vaginosis had recurrence within 12 months.

Condoms Reduce HPV Acquisition in Heterosexual Women

The more frequently condoms were used, the lower the risk for HPV infection.

Incidence of Vulvar Carcinoma Increasing

A clear association exists between HPV and in situ vulvar carcinoma; the association is less clear for invasive cancer.

Modeling the Survival Benefits of HIV Treatment in the U.S.

HIV treatments saved about 3 million years of life from 1989 through 2003 — or about 13 years per treated person.

Condoms Protect Against HPV Infection in Young Women

In a well-designed prospective study, consistent condom use reduced the risk for cervical and vulvovaginal HPV infection.

Concurrent Treatment of HIV and TB

New case-control results add to a growing body of evidence that supports aggressively treating both HIV and TB.

Large Household Survey May Not Provide Accurate HIV Information

Data indicating stable HIV seroprevalence rates over the last decade are probably flawed.

Blurred Vision in HIV-Infected Patients: Think Ocular Syphilis

Over a 13-month period in one clinic, ocular syphilis was diagnosed in three patients taking potent ART.

AIDS: The First 25 Years

Reflections on the first 25 years of the HIV/AIDS pandemic

DHHS Treatment Guidelines Updated

New HIV treatment guidelines include updates on genotypic resistance testing and treatment interruptions.

How Long Will Vaccines Against HPV Remain Effective?

A new study indicates that the answer is at least 4 years.

Antiretroviral Therapy During Pregnancy: How Safe?

Combination therapy that includes a protease inhibitor may increase the risk for preterm delivery.

As with Squamous Tumors, HPV Is Key in Cervical Adenocarcinoma Etiology

HPV infection was associated with an 80-fold increase in risk for cervical adenocarcinoma.

Genital Herpes in Heterosexual Men

Most heterosexual men with HSV-2 infection were unaware of their disease status.

Spectinomycin Discontinued as Treatment for Gonorrhea

Ceftriaxone is the only remaining alternative treatment for quinolone-resistant gonorrhea in the U.S.

Skin Findings in HIV Disease

Highly active antiretroviral treatment has lessened the prevalence of troubling cutaneous disease in patients with HIV.

Media Exposure and Early Sexual Intercourse

Exposure to sexually explicit content increases risk for early sexual intercourse among teens.

Evolving Mortality Patterns in HIV-Infected Patients

A report from U.S. military clinics documents steadily improving clinical outcomes for HIV-infected individuals and a shift to non-AIDS–related conditions as the primary causes of death.

After M184V, Continue the 3TC

Patients with the M184V mutation who continued 3TC alone, instead of stopping all treatment, had virologic and clinical benefits, and no new resistance mutations were observed.

The Cost-Effectiveness of Expanding Prevention Programs

Implementing comprehensive HIV prevention programs in low- and middle-income countries would yield long-term cost savings.

Items 426-450 of 509 are shown

Search

Advanced

Sign-In

Forgot your password?

New to Journal Watch?





Copyright © 2009. Massachusetts Medical Society. All rights reserved.